GAPDHP60

Across TCGA pan-cancer cohorts, GAPDHP60 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of GAPDHP60’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where GAPDHP60 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types GAPDHP60 is over-expressed in tumor.

KIRC, COAD, and HNSC are the cancer types where GAPDHP60 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GAPDHP60 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	II,III,IV	+0.674	<.001	12	view →
COAD	Female	II,III,IV	+0.932	<.001	10	view →
HNSC	Male	All	+0.414	<.001	10	view →
LIHC	Female	II,III,IV	+0.355	<.001	9	view →
LUAD	Female	II,III,IV	+0.567	<.001	8	view →
LUSC	Female	II,III,IV	+0.688	<.001	7	view →
UCEC	All	All	+0.648	<.001	6	view →
BRCA	All	II,III,IV	+0.270	<.001	6	view →
KIRP	All	All	+0.263	.001	5	view →
READ	All	All	+0.373	.020	2	view →
CHOL	All	All	+0.150	.015	1	view →
KICH	All	All	+0.105	.029	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

GAPDHP60–KIRC

Open the KIRC breakdown →